Introduction to DAPT in BAD-related stroke

Branch Atheromatous Disease (BAD) represents a distinct and often challenging subtype of ischemic stroke. It is primarily characterized by microatheroma at the orifice of large perforating arteries, such as the lenticulostriate or paramedian pontine arteries. Management remains debated within the neurological community. Specifically, clinicians frequently weigh the benefits of DAPT in BAD-related stroke against single antiplatelet therapy (SAPT). A recent multicenter propensity-matched cohort analysis by Hu H et al. provides essential insights into this clinical dilemma. The study investigated the efficacy and safety of DAPT in BAD-related stroke, focusing on functional outcomes at 90 days. While previous trials like CHANCE and POINT have established the role of DAPT in minor strokes, the specific application of DAPT in BAD-related stroke requires nuanced understanding. This article explores the findings of this pivotal study and its implications for modern stroke management. By analyzing 449 patients, the researchers sought to clarify whether intensive antiplatelet regimens offer a definitive advantage in achieving excellent functional recovery. Understanding these nuances is vital for optimizing patient care in acute settings. Consequently, the data provided here serves as a critical update for practitioners managing subcortical infarcts.

Understanding the Pathophysiology of Branch Atheromatous Disease

Understanding the unique pathophysiology is essential to appreciate the therapeutic challenges. Unlike typical lacunar strokes caused by lipohyalinosis of small distal vessels, BAD involves larger perforating branches. These vessels are typically 700 to 800 micrometers in diameter. The occlusion occurs at the proximal portion of the branch. This is often due to an extension of a parent artery plaque or an isolated microatheroma. Consequently, the resulting infarcts are usually larger and involve a more significant volume of the subcortical tissue. This anatomical distinction is crucial because BAD is frequently associated with early neurological deterioration (END) and progressive motor deficits. Patients may present with minor symptoms that rapidly worsen over the first 48 to 72 hours. This "stuttering" progression is a hallmark of the disease. Therefore, traditional treatment strategies for lacunar infarcts might not be sufficiently aggressive for BAD. Researchers have hypothesized that DAPT could stabilize the plaque and prevent further luminal narrowing. However, clinical evidence has remained inconclusive until recently. By targeting multiple pathways of platelet activation, clinicians hope to mitigate the risk of fluctuating deficits. This approach aligns with the understanding that atherosclerosis drives the underlying disease process in these specific cases.

Research Methodology and Propensity Score Matching

The study conducted by Hu H et al. utilized a robust multicenter prospective design to evaluate treatment outcomes. From the registry, investigators collected data from consecutive patients diagnosed with BAD-related stroke. To ensure a rigorous comparison, they applied Propensity Score Matching (PSM). This statistical technique is vital in observational studies to balance baseline characteristics between the SAPT and DAPT groups. Initially, the researchers enrolled a total of 449 patients. After applying PSM, they narrowed the cohort to 112 patients in the SAPT group and 171 in the DAPT group. The median age of participants was 60 years. This reflects a relatively young stroke population often seen in clinical practice. Furthermore, the median National Institutes of Health Stroke Scale (NIHSS) score at admission was 3, indicating mild baseline severity. The primary efficacy endpoint was an "excellent outcome," defined as a modified Rankin Scale (mRS) score of 0 to 1 at the 90-day mark. Safety was primarily assessed through the occurrence of bleeding events within the first week and at 90 days. This methodology allows for a clearer understanding of how real-world therapeutic choices impact long-term disability without the inherent biases of non-randomized treatment allocation.

Comparative Analysis: DAPT in BAD-related Stroke

The analysis results offer a complex picture regarding the efficacy of DAPT in BAD-related stroke. Specifically, an excellent functional outcome occurred in 69.6% of the SAPT group compared to 79.5% in the DAPT group. The DAPT group showed a higher recovery percentage. However, the difference did not reach statistical significance. The calculated odds ratio was 0.590 with a p-value of 0.059. This near-significant result suggests a strong numerical trend favoring DAPT but lacks the definitive weight of a strictly positive trial. Moreover, other efficacy outcomes showed no significant differences between the two treatment arms. Subgroup analyses were also performed to identify specific patient populations that might benefit more from intensive therapy. However, after correcting for multiple comparisons, no within-subgroup differences remained statistically significant. This lack of statistical superiority highlights the need for larger, randomized trials. Nevertheless, the almost 10% numerical difference in excellent outcomes is clinically noteworthy. For many practitioners, this trend reinforces the potential utility of DAPT in preventing long-term disability. Consequently, the decision between DAPT and SAPT remains individualized, guided by clinical judgment and patient-specific risk factors. Therefore, while not mandatory, DAPT remains a logical choice for high-risk patients.

Safety Profiles and Bleeding Risk Assessment

Safety is a paramount concern whenever intensive antithrombotic therapy is prescribed, especially in the context of acute stroke. A significant finding of this cohort analysis was the safety profile of DAPT. The investigators observed no increased risk of bleeding events in the DAPT group compared to the SAPT group. This safety was consistent both in the early phase (within 7 days) and throughout the 90-day follow-up period. Historically, clinicians have been cautious about combining aspirin and clopidogrel due to fears of symptomatic intracranial hemorrhage or major systemic bleeding. However, this study suggests that in the specific context of BAD-related stroke, DAPT is well-tolerated. This finding is particularly important because BAD patients often have a low risk of hemorrhagic transformation compared to those with large-vessel cardioembolic strokes. Furthermore, the absence of significant treatment-by-subgroup interactions for safety outcomes suggests that the safety profile is broadly applicable across different patient demographics. Therefore, while the efficacy advantage was not statistically proven, the lack of a safety penalty makes DAPT a viable clinical option. Clinicians can consider DAPT for its potential neuroprotective and plaque-stabilizing benefits without excessive concern for compromising patient safety. This balance of risk and reward is central to modern evidence-based neurology.

Strategic Clinical Considerations for Modern Practice

For Indian neurologists and internists, these findings carry significant weight. Stroke remains a major health burden in the subcontinent, frequently complicated by high rates of uncontrolled hypertension and metabolic syndrome. These comorbidities are key drivers of atherosclerosis and, by extension, Branch Atheromatous Disease. Consequently, Indian physicians often encounter the "stuttering stroke" pattern typical of BAD. When managing such patients, the numerical trend toward benefit with DAPT provides a practical framework. Even if not statistically superior, the 10% absolute increase in excellent outcomes might justify DAPT usage. This is especially true in patients with high risks of clinical progression. Furthermore, the proven safety of the DAPT regimen in this study aligns with local clinical experience. Early aggressive intervention is often necessary to preserve functional independence. However, physicians must remain mindful of the need for further investigation and the potential for individualized therapy. It is also essential to continue focusing on primary and secondary prevention through rigorous blood pressure and lipid management. As we await more definitive randomized controlled trials, this multicenter analysis serves as a valuable bridge. It supports a more intensive approach to antiplatelet therapy in appropriate candidates. Ultimately, the goal remains the optimization of functional recovery and the minimization of long-term disability.

FAQ: Frequently Asked Questions

How does Branch Atheromatous Disease differ from standard lacunar infarction?

Branch Atheromatous Disease involves the occlusion of a large perforating artery at its origin, usually due to microatheroma or parent artery plaque. In contrast, standard lacunar infarcts typically result from lipohyalinosis of smaller, distal vessels. Therefore, BAD lesions are often larger and more likely to cause progressive neurological deterioration. Clinicians must distinguish these entities because BAD requires more aggressive management to prevent the worsening of motor deficits during the acute phase of treatment.

What does the numerical trend in functional outcomes imply for clinical practice?

The study showed that 79.5% of DAPT patients achieved an excellent outcome compared to 69.6% of SAPT patients. Although the p-value of 0.059 was not statistically significant, the 10% difference suggests a potential clinical benefit. For many physicians, this trend justifies the use of DAPT, especially since no increased bleeding risk was observed. It underscores the possibility that DAPT provides a protective effect that larger studies might eventually confirm as statistically significant in later trials.

Is dual antiplatelet therapy safe for long-term use in BAD patients?

The multicenter analysis focused on outcomes and safety up to 90 days, finding no significant increase in bleeding risks. Consequently, DAPT is considered safe for the short-to-medium term in this specific population. However, the optimal duration beyond 90 days remains a subject for further research. Most guidelines suggest transitioning back to single antiplatelet therapy for long-term secondary prevention to minimize cumulative bleeding risks while maintaining protection against recurrent ischemic events in these chronic patients.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice or a professional relationship. Always seek the advice of a physician or other qualified health provider with any questions regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

Hu H et al. Dual Antiplatelet Therapy in Acute Branch Atheromatous Disease (BAD)-Related Stroke: A Multicenter Propensity-Matched Cohort Analysis. CNS Neurosci Ther. 2026 Jul undefined. doi: 10.1002/cns.71005. PMID: 42378031.

Niimi M, et al. Comparison of Functional Outcome between Lacunar Infarction and Branch Atheromatous Disease in Lenticulostriate Artery Territory. J Stroke Cerebrovasc Dis. 2016;25(9):2271-5.

Xu Z, et al. Effect of Argatroban Plus Dual Antiplatelet in Branch Atherosclerosis Disease: A Randomized Clinical Trial. Stroke. 2025;56(6):1662-1670.